MHRA Offers Medtechs Extra Transition Time For UK Regulatory System Compliance
UK regulator to allow three- and five-year transitions for CE-marked devices and diagnostics
26 June saw the release finally of the UK government’s official response to the MHRA’s 2021 consultation on its post-Brexit medical devices regulatory framework. The considered response, held up by political and internal timing issues, represents an implementation plan for reform of the system. Crucially it allows industry extra compliance time.
You may also be interested in...
There is potential for ethnic and socio-economic bias in medical device design, funding allocation and regulatory guidelines, according to the UK’s Department of Health and Social Care (DHSC), which has commissioned a review to uncover the extent of the problem.
The spotlight is on IVDs in the post-COVID phase. Innovators in university spin-outs and the established industry have responded with new technologies, creating a vibrant scene. Regulators and reimbursors must not disrupt the momentum, say BIVDA’s regulatory affairs manager Ashleigh Batchen and chief executive Doris-Ann Williams.
The role and purpose of medical device regulation is now better understood than at any time in its history, and regulators are no longer seen as gatekeepers preventing business from happening. Graeme Tunbridge, formerly at the MHRA and now a senior VP at leading conformity assessment body BSI, is a champion of the climate of inclusivity.